On November 9, 2026 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, reported financial results for the third quarter ended September 30, 2026 and recent business and scientific highlights.
predicted subtherapeutic dose to assess pharmacokinetics and safety in PV patients. Following completion of the sentinel group, the safety monitoring committee will advise on dose selection for Part 1, an open-label, single-arm, dose escalation, 28-week evaluation of epetraborole to maintain hematocrit control and reduce the frequency of phlebotomy in patients with phlebotomy-dependent PV. The Company anticipates releasing Part 1 data periodically throughout 2027.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In August 2026, the Company presented four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole in PV at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. In October 2026, the Company presented a poster at the18th International Congress on Myeloproliferative Neoplasms detailing the design of its Phase 2 clinical trial evaluating epetraborole in patients with PV.
M. abscessus complex lung disease
•
Enrollment ongoing in Phase 2 investigator-initiated clinical trial of epetraborole in patients with M. abscessus lung disease
Building on the microbiological and safety data from the Company’s prior non-tuberculous mycobacterial (NTM) study in treatment-refractory Mycobacterium avium complex (MAC), the Company believes that epetraborole has the potential to address a critical unmet need in M. abscessus lung disease, one of the most difficult-to-treat NTM infections for which no FDA-approved therapy exists. The Company is supporting an investigator-initiated trial of oral epetraborole in M. abscessus and anticipates that data from this study, if positive, could provide clinical proof-of-concept in M. abscessus lung disease and thereby inform the design of a subsequent pivotal trial. Patient enrollment is ongoing. The 84-patient, multicenter, randomized, double-blind, placebo-controlled, prospective clinical study is being led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at the Oregon Health and Science University, in conjunction with other investigators across an estimated 10 to 15 sites in the U.S. The Company anticipates reporting topline results in late 2027, subject to enrollment progress.
Chagas disease
•
Advancing startup activities for a Phase 2 proof-of-concept study in chronic Chagas disease
The Company is advancing AN2-502998 (formerly known as AN15368), an oral, boron-based small molecule CPSF3 inhibitor for the treatment of chronic Chagas disease, also known as American trypanosomiasis. Chagas disease is caused by the parasite Trypanosoma cruzi (T. cruzi). Over 300,000 people are estimated to be infected in the U.S., 200,000 across Europe and Japan, and 10 million worldwide. Left untreated, chronic T. cruzi infection is lifelong and can be life threatening. The parasite T. cruzi silently damages the heart and digestive system, with approximately 20-30% of people developing serious cardiac damage resulting in heart failure, stroke or sudden death. There are no FDA-approved treatments for adults with Chagas disease.
AN2-502998 is the only compound of which the Company is aware to have demonstrated curative activity in preclinical studies across multiple species, including in nonhuman primates with long-term, naturally acquired chronic infections caused by diverse T. cruzi genetic types. The Company believes that efficacy in naturally infected nonhuman primates is the mostclinically relevant predictor of efficacy for human chronic Chagas disease. Startup activities are underway for a Phase 2 proof-of-concept study in adults with chronic T. cruzi infection.
Boron chemistry pipeline
•
AN2-504661 selected as an oral development candidate for hypophosphatasia (HPP)
The Company recently selected AN2-504661 as its development candidate for the treatment of HPP. HPP is a rare inherited metabolic bone disease, resulting in impaired mineralization of bone and teeth. AN2-504661 is an oral, boron-based inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and was selected following extensive lead optimization and preclinical evaluation demonstrating the potential for a differentiated profile characterized by potent and selective ENPP1 inhibition, favorable pharmacokinetic properties and oral bioavailability, efficacy in animal models, and an encouraging nonclinical safety profile with low potential for hERG-related cardiac effects and other safety liabilities, supporting its potential to be best-in-class. The Company plans to initiate a Phase 1 clinical study for AN2-504661 in the second half of 2027.
•
Extension of funding for tuberculosis research collaboration with GSK
In September, the Company announced that the Gates Foundation awarded an extension of funding to support AN2’s research activities under its ongoing tuberculosis research collaboration with GSK. TB remains one of the leading causes of death from an infectious disease worldwide.
Corporate Update
•
Appointed Cameron Trenor, M.D., as Chief Medical Officer
In August, the Company appointed Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology.
"The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform," said Eric Easom, Co-Founder, Chairman, President and CEO of AN2 Therapeutics. "With FDA IND clearance for epetraborole in polycythemia vera, we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities. We also recently presented the Phase 2 study design at the MPN Congress, while continuing to advance our programs in M. abscessus and Chagas disease. Beyond our clinical stage pipeline, the selection of AN2-504661 for HPP as our second development candidate this year, further demonstrates the productivity of our research organization and the potential of our boron chemistry platform to generate differentiated therapies across multiple disease areas. With multiple clinical and development milestones ahead, we believe we are well positioned to continue building value across a diverse pipeline of differentiated boron-based therapies."
Third Quarter & Recent Business Updates:
Polycythemia vera (PV)
•
Phase 2 global study of oral epetraborole in PV cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end
Startup activities are underway for a global Phase 2 study to evaluate the efficacy and safety of oral epetraborole in adults with phlebotomy-dependent PV. The Company has received regulatory clearance to proceed in all planned jurisdictions, including U.S. FDA clearance of its IND, and regulatory clearances in Australia and India. The Company anticipates commencing enrollment by the end of 2026, beginning with an open-label sentinel cohort receiving a predicted subtherapeutic dose to assess pharmacokinetics and safety in PV patients. Following completion of the sentinel group, the safety monitoring committee will advise on dose selection for Part 1, an open-label, single-arm, dose escalation, 28-week evaluation of epetraborole to maintain hematocrit control and reduce the frequency of phlebotomy in patients with phlebotomy-dependent PV. The Company anticipates releasing Part 1 data periodically throughout 2027.
In August 2026, the Company presented four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole in PV at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. In October 2026, the Company presented a poster at the18th International Congress on Myeloproliferative Neoplasms detailing the design of its Phase 2 clinical trial evaluating epetraborole in patients with PV.
M. abscessus complex lung disease
•
Enrollment ongoing in Phase 2 investigator-initiated clinical trial of epetraborole in patients with M. abscessus lung disease
Building on the microbiological and safety data from the Company’s prior non-tuberculous mycobacterial (NTM) study in treatment-refractory Mycobacterium avium complex (MAC), the Company believes that epetraborole has the potential to address a critical unmet need in M. abscessus lung disease, one of the most difficult-to-treat NTM infections for which no FDA-approved therapy exists. The Company is supporting an investigator-initiated trial of oral epetraborole in M. abscessus and anticipates that data from this study, if positive, could provide clinical proof-of-concept in M. abscessus lung disease and thereby inform the design of a subsequent pivotal trial. Patient enrollment is ongoing. The 84-patient, multicenter, randomized, double-blind, placebo-controlled, prospective clinical study is being led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at the Oregon Health and Science University, in conjunction with other investigators across an estimated 10 to 15 sites in the U.S. The Company anticipates reporting topline results in late 2027, subject to enrollment progress.
Chagas disease
•
Advancing startup activities for a Phase 2 proof-of-concept study in chronic Chagas disease
The Company is advancing AN2-502998 (formerly known as AN15368), an oral, boron-based small molecule CPSF3 inhibitor for the treatment of chronic Chagas disease, also known as American trypanosomiasis. Chagas disease is caused by the parasite Trypanosoma cruzi (T. cruzi). Over 300,000 people are estimated to be infected in the U.S., 200,000 across Europe and Japan, and 10 million worldwide. Left untreated, chronic T. cruzi infection is lifelong and can be life threatening. The parasite T. cruzi silently damages the heart and digestive system, with approximately 20-30% of people developing serious cardiac damage resulting in heart failure, stroke or sudden death. There are no FDA-approved treatments for adults with Chagas disease.
AN2-502998 is the only compound of which the Company is aware to have demonstrated curative activity in preclinical studies across multiple species, including in nonhuman primates with long-term, naturally acquired chronic infections caused by diverse T. cruzi genetic types. The Company believes that efficacy in naturally infected nonhuman primates is the most clinically relevant predictor of efficacy for human chronic Chagas disease. Startup activities are underway for a Phase 2 proof-of-concept study in adults with chronic T. cruzi infection.
Boron chemistry pipeline
•
AN2-504661 selected as an oral development candidate for hypophosphatasia (HPP)
The Company recently selected AN2-504661 as its development candidate for the treatment of HPP. HPP is a rare inherited metabolic bone disease, resulting in impaired mineralization of bone and teeth. AN2-504661 is an oral, boron-based inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and was selected following extensive lead optimization and preclinical evaluation demonstrating the potential for a differentiated profile characterized by potent and selective ENPP1 inhibition, favorable pharmacokinetic properties and oral bioavailability, efficacy in animal models, and an encouraging nonclinical safety profile with low potential for hERG-related cardiac effects and other safety liabilities, supporting its potential to be best-in-class. The Company plans to initiate a Phase 1 clinical study for AN2-504661 in the second half of 2027.
•
Extension of funding for tuberculosis research collaboration with GSK
In September, the Company announced that the Gates Foundation awarded an extension of funding to support AN2’s research activities under its ongoing tuberculosis research collaboration with GSK. TB remains one of the leading causes of death from an infectious disease worldwide.
Corporate Update
•
Appointed Cameron Trenor, M.D., as Chief Medical Officer
In August, the Company appointed Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology.
Selected Third Quarter Financial Results
•
Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2026 were $5.7 million, compared to $7.0 million for the same period during 2025 due to decreased preclinical and research studies expenses, other miscellaneous expenses, and clinical trial expenses. These decreases were partially offset by increases in personnel-related expenses and chemistry manufacturing and controls (CMC) expenses.
•
General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2026 were $2.9 million, compared to $3.0 million for the same period in 2025 due to decreased personnel-related expenses, partially offset by increased professional and outside services expenses and other miscellaneous expenses.
•
Interest Income: Interest income for the third quarter of 2026 was $0.7 million, consistent with $0.7 million for the same period during 2025.
•
Net Loss: Net loss for the third quarter of 2026 was $8.0 million, compared to $9.4 million for the same period during 2025.
•
Cash Position: The Company had cash, cash equivalents and investments of $80.2 million as of September 30, 2026. The Company projects that existing cash, cash equivalents, and investments will sustain operations into 2029 under the current operating plan.
(Press release, AN2 Therapeutics, NOV 9, 2026, View Source [SID1234674462])